https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma

High Response Rates With Talquetamab Plus Teclistamab in Triple-Class Refractory Multiple Myeloma

Talquetamab and teclistamab showed significant promise in a phase 1b/2 dose escalation and expansion trial.

administrator

Related Articles